Section Arrow
PMCB.NASDAQ
- PharmaCyte Biotech
Quotes are at least 15-min delayed:2025/07/21 06:41 EDT
Pre Market
Last
 1.03
0 (0.00%)
Bid
0.7795
Ask
1.43
High 1.03 
Low 1.03 
Volume 10 
Regular Hours
Last
 1.03
+0.01 (+0.98%)
Day High 
1.06 
Prev. Close
1.02 
1-M High
1.15 
Volume 
35.73K 
Bid
0.7795
Ask
1.43
Day Low
Open
1.03 
1-M Low
Market Cap 
7.00M 
Currency USD 
P/E 0.75 
%Yield -- 
10-SMA 1.09 
20-SMA 1.08 
50-SMA 1.07 
52-W High 2.4229 
52-W Low
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.34/-0.38
Enterprise Value
7.00M
Balance Sheet
Book Value Per Share
5.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.1 -0.975 -6.93%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulationtechnology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.